Elucida Oncology, Inc. Elucida Oncology, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Platform
    • Pipeline
    • Publications
  • Careers
  • News & Media
    • Overview
    • Press Releases
    • Media
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Media

News & Media

  • Overview
  • Press Releases
  • Media
  • Presentations
  • Email Alerts

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer

Nov 22, 2021

Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)

Sep 17, 2021

Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha

Jul 19, 2021

Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board

Apr 29, 2021

Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting

Mar 29, 2021

Elucida Oncology Closes $44 Million Series A-1 Financing

Jan 12, 2021

Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 7, 2021

Elucida Oncology Appoints Dr. Eliel Bayever as Chief Medical Officer

Oct 1, 2020

Elucida Oncology Taps Geno J. Germano, Veteran Pfizer Executive and Former Intrexon President, as New CEO

Aug 22, 2018

Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles

Jun 20, 2018
    • 1
    • 2
    • 3
    © 2023 Elucida Oncology, Inc. All Rights Reserved. The Elucida Oncology™ name and Logo and Target or Clear™ are trademarks of Elucida Oncology, Inc.
    Privacy Policy Disclaimer Terms of Use Sitemap